A recent study used Mendelian randomization, which uses genetic variants to randomly allocate individuals to groups based on genotype, to further investigate the causal relationship between body mass index (BMI) and psoriasis. It found that as BMI rises, so too does the risk for developing psoriasis.
Psoriasis is understood to have a link with obesity, but a causal relationship between body mass and psoriasis has not been established. Some have suggested that obesity could promote skin inflammation, although it may also be the case that skin disorders may lead to reduced physical activity and contribute to higher weight.
A recent study used Mendelian randomization, which uses genetic variants to randomly allocate individuals to groups based on genotype, to further investigate the causal relationship between body mass index (BMI) and psoriasis. It found that as BMI rises, so too does the risk for developing psoriasis.
The researchers used data for 396,495 participants whose individual-level data were contained in UK and Norwegian databases and 356,926 participants who had summary-level data available. Genotyping of participants was performed using 1 of several arrays, and logistic regression models were used to estimate the observational association between BMI and psoriasis. These analyses were adjusted for age, sex, smoking status, alcohol intake, and educational level.
The Mendelian randomization showed that a 1 kg/m2 increase in BMI was associated with an 8% increase in the risk of psoriasis. Similar causal estimates were found even when stratifying cases of psoriasis by patients’ self-reports and those defined by data extraction efforts.
While the study was limited by factors such as patient reporting of psoriasis and the fact that the participants studied were only of European ancestry, the findings do suggest that approaches to preventing and treating psoriasis may benefit from targeting adiposity levels in addition to immune pathways in the skin.
“We still don't know enough about the mechanisms behind this connection,” said Mari Løset, MD, one of the study’s authors, in a statement about her team’s findings. “Fatty tissue is an organ that produces hormones and inflammatory signaling molecules, which could be a contributing factor.”
Løset added that “Psoriasis is a very complex disease and we hope to study subgroups, especially individuals with severe psoriasis. The hypothesis is that we will be able to observe even greater links with higher weight.”
Reference
Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study [published online January 31, 2019]. PLoS Med. doi: 10.1371/journal.pmed.1002739.
Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis
March 18th 2024Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.
Read More
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Quality of Life, Severity Scales Correlated in Patients With Psoriasis Worldwide
March 13th 2024Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
Read More